14-day Premium Trial Subscription Sign Up For FreeGet Free

Stock Market Week 20 - The Game Is On! Click to watch.

Axsome Therapeutics Stock Forecast

NASDAQ:AXSM BUY SELL

$30.82 (10.47%)

Volume: 574.984k

Closed: May 16, 2022

Hollow Logo Score: -1.848

Axsome Therapeutics Stock Forecast

BUY SELL NASDAQ:AXSM
$30.82 (10.47%)

Volume: 574.984k

Closed: May 16, 2022

Score Hollow Logo -1.848

Axsome Therapeutics Stock Forecast NASDAQ:AXSM

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-03 58.99% Mizuho $51.00 $49.00 Maintains Buy
2022-04-27 -12.39% Morgan Stanley $34.00 $27.00 Maintains Equal-Weight
2022-03-29 149.84% Jefferies $71.00 $77.00 Maintains Buy
2022-03-02 62.23% SVB Leerink $65.00 $50.00 Maintains Outperform
2021-11-09 110.9% SVB Leerink $75.00 $65.00 Maintains Outperform
2021-08-30 484.04% HC Wainwright & Co. $225.00 $180.00 Maintains Buy
2021-08-10 419.14% Truist Securities $200.00 $160.00 Maintains Buy
2021-08-10 10.32% Morgan Stanley $105.00 $34.00 Downgrades Overweight Equal-Weight
2021-08-10 143.35% SVB Leerink $115.00 $75.00 Maintains Outperform
2021-08-10 78.46% Mizuho $118.00 $55.00 Maintains Buy
2021-06-10 263.4% Berenberg $112.00 Initiates Coverage On Buy
2021-05-26 240.69% Morgan Stanley $104.00 $105.00 Maintains Overweight
2021-04-27 630.05% HC Wainwright & Co. $210.00 $225.00 Maintains Buy
2021-03-02 237.44% Morgan Stanley $101.00 $104.00 Maintains Overweight
2021-01-08 318.56% Jefferies $129.00 Initiates Coverage On Buy
2020-12-16 289.36% Mizuho $120.00 Initiates Coverage On Buy
2020-11-09 227.71% Morgan Stanley $102.00 $101.00 Maintains Overweight
2020-09-29 114.15% B of A Securities $66.00 Initiates Coverage On Underperform
2020-09-10 230.95% Morgan Stanley $102.00 Initiates Coverage On Overweight
2020-04-28 581.38% HC Wainwright & Co. $200.00 $210.00 Maintains Buy
2020-04-28 325.05% Cantor Fitzgerald $125.00 $131.00 Maintains Overweight
2020-04-14 208.24% Cowen & Co. $95.00 Initiates Coverage On Outperform
2019-12-30 305.58% Cantor Fitzgerald $104.00 $125.00 Reiterates Overweight
2019-12-30 548.93% HC Wainwright & Co. $170.00 $200.00 Maintains Buy
2019-12-16 412.65% Guggenheim $65.00 $158.00 Maintains Buy
2019-12-16 237.44% Cantor Fitzgerald $55.00 $104.00 Maintains Overweight
2019-10-16 55.74% Guggenheim $48.00 Initiates Coverage On Buy
2019-09-18 - William Blair - Initiates Coverage On Outperform

AXSM Stock Trend

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 7.81% during the next 3 months and, with a 90% probability hold a price between $27.44 and $52.16 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-05-18 $25.52 $36.98 $48.44
2022-05-19 $25.57 $37.04 $48.50
2022-05-20 $25.63 $37.10 $48.56
2022-05-23 $25.69 $37.15 $48.62
2022-05-24 $25.75 $37.21 $48.68
2022-05-25 $25.81 $37.27 $48.74
2022-05-26 $25.87 $37.33 $48.79
2022-05-27 $25.92 $37.39 $48.85
2022-05-31 $25.98 $37.45 $48.91
2022-06-01 $26.04 $37.50 $48.97
2022-06-02 $26.10 $37.56 $49.03
2022-06-03 $26.16 $37.62 $49.09
2022-06-06 $26.22 $37.68 $49.14
2022-06-07 $26.27 $37.74 $49.20
2022-06-08 $26.33 $37.80 $49.26
2022-06-09 $26.39 $37.86 $49.32
2022-06-10 $26.45 $37.91 $49.38
2022-06-13 $26.51 $37.97 $49.44
2022-06-14 $26.57 $38.03 $49.49
2022-06-15 $26.62 $38.09 $49.55
2022-06-16 $26.68 $38.15 $49.61
2022-06-17 $26.74 $38.21 $49.67
2022-06-21 $26.80 $38.26 $49.73
2022-06-22 $26.86 $38.32 $49.79
2022-06-23 $26.92 $38.38 $49.84
2022-06-24 $26.97 $38.44 $49.90
2022-06-27 $27.03 $38.50 $49.96
2022-06-28 $27.09 $38.56 $50.02
2022-06-29 $27.15 $38.61 $50.08
2022-06-30 $27.21 $38.67 $50.14

About Axsome Therapeutics

Axsome Therapeutics Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT